Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis (SSc–ILD): impact on therapy.

[Joelf]

Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis (SSc–ILD): impact on therapy.

 

In the management of SSc–ILD, a multidisciplinary team approach which integrates physiology and radiology with the patient at the centre of the process is crucial for effective management and provision of the best outcomes. PubMed, Expert Rev Clin Immunol, 01/10/2018. (Also see Treatments for Pulmonary Fibrosis)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.